欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Atuveciclib Racemate_1414943-88-6_产品详情
1414943-88-6
  • Atuveciclib Racemate

  • names:

    Atuveciclib Racemate

  • CAS号:

    1414943-88-6

    MDL Number:
  • MF(分子式): C18H18FN5O2S MW(分子量): 387.43
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Atuveciclib Racemate
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM002249-5mg 5mg 98.48% ¥ 4725.00 ¥ 4725.00 2-3天
- +
¥ 0.00
YZM002249-1mg 1mg 98.48% ¥ 1950.00 ¥ 1950.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 1414943-88-6
Inchi
InchiKey
分子式 Formula C18H18FN5O2S
分子量 Molecular Weight 387.43
溶解度Solubility
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
Atuveciclib Racemate(CAS:1414943-88-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Atuveciclib Racemate (BAY-1143572 Racemate) 为 Atuveciclib 的外消旋混合物
IntroductionAtuveciclib Racemate (BAY143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oralPEFb/CDK9inhibitor which supressesCDK9/CycT1with anIC50of 13 nM.
Application1
Application2
Application3
Atuveciclib Racemate (BAY-1143572 Racemate) 为 Atuveciclib 的外消旋混合物。 Atuveciclib 是一种有效的且高选择性的口服P-TEFb/CDK9抑制剂,CDK9/CycT1的IC50为13 nM。Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oralP-TEFb/CDK9inhibitor which supressesCDK9/CycT1with anIC50of 13 nM.
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3022.
【2】.Scholz A, et al. BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr DDT02-02. doi:10.1158/1538-7445.AM2015-DDT02-02
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents